
China Pharma Holdings CPHI
€ 0.53
-2.26%
Quartalsbericht 2025-Q3
hinzugefügt 12.11.2025
China Pharma Holdings Langfristige Verbindlichkeiten 2011-2026 | CPHI
Langfristige Verbindlichkeiten Jährlich China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.71 M | 2.95 M | 5.13 M | 7.65 M | 9.21 M | 11.8 M | 11.7 M | 12.7 M | 96 K | 129 K |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 12.7 M | 96 K | 6.3 M |
Langfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aurora Cannabis
ACB
|
681 M | $ 3.54 | 2.46 % | $ 86.3 M | ||
|
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
10.7 M | $ 2.57 | 1.1 % | $ 1.34 B | ||
|
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | ||
|
Assertio Holdings
ASRT
|
115 M | $ 12.34 | 4.86 % | $ 79 M | ||
|
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
134 M | - | - | $ 2.06 B | ||
|
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | ||
|
Evolus
EOLS
|
102 M | $ 5.03 | -0.2 % | $ 324 M | ||
|
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | ||
|
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 3.06 | -0.16 % | $ 43 M | ||
|
Jupiter Wellness
JUPW
|
6.38 K | - | - | $ 33.6 M | ||
|
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | ||
|
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M | ||
|
Harrow Health
HROW
|
19.8 M | $ 35.27 | 1.03 % | $ 1.3 B | ||
|
Organogenesis Holdings
ORGO
|
105 M | $ 2.54 | -1.55 % | $ 334 M | ||
|
Pacira BioSciences
PCRX
|
368 M | $ 21.82 | -3.83 % | $ 1.01 B | ||
|
Emergent BioSolutions
EBS
|
1.02 B | $ 8.14 | -2.28 % | $ 417 M | ||
|
OrganiGram Holdings
OGI
|
107 M | $ 1.45 | 1.76 % | $ 402 M | ||
|
Sundial Growers
SNDL
|
1.03 M | $ 1.45 | 0.84 % | $ 3.37 M | ||
|
Veru
VERU
|
6.71 M | $ 2.44 | 2.74 % | $ 329 M | ||
|
ProPhase Labs
PRPH
|
7.94 M | - | - | $ 5.07 M | ||
|
TherapeuticsMD
TXMD
|
246 M | $ 2.26 | 4.15 % | $ 23.6 M | ||
|
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | ||
|
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | ||
|
Viatris
VTRS
|
13.8 B | $ 13.91 | 2.92 % | $ 16.7 B | ||
|
Perrigo Company plc
PRGO
|
4.59 B | $ 10.38 | 6.79 % | $ 1.44 B | ||
|
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 2.44 | 1.22 % | $ 3.03 M | ||
|
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.42 | 3.8 % | $ 193 M | ||
|
Rockwell Medical
RMTI
|
11.6 M | $ 1.06 | 10.44 % | $ 24.7 M | ||
|
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
53.4 M | $ 0.92 | 2.34 % | $ 45.9 M | ||
|
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | ||
|
Solid Biosciences
SLDB
|
21.2 M | $ 7.79 | 4.08 % | $ 318 M | ||
|
Tilray
TLRY
|
570 M | $ 7.0 | 1.38 % | $ 4.33 B | ||
|
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | ||
|
cbdMD
YCBD
|
2.49 M | $ 0.76 | 4.11 % | $ 3.28 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M | ||
|
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M |